A multicenter, randomized, double-blind, placebo-controlled, dose-range Phase II study to assess the efficacy and safety of GIA632 in patients with non-segmental vitiligo not adequately controlled with topical therapies [GIA632B12201 Vitiligo]. (NCT07431177)
CGIA632B12201 VITESS
This trial is investigating the safety and efficacy of GIA632 in adults with non-segmental vitiligo vs placebo. This trial lasts approximately one year and ongoing treatment is available for eligible participants. GIA632 is given via a subcut injection (injection into the stomach tissue) at fortnightly intervals.
Program & service
This trial is being run with the Specialty Medicine service, and as part of the Dermatology program.
Trial phase
Phase 2
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Prof Johannes S Kern
Key inclusion data
Over 18 years of age with a confirmed diagnosis of non-segmental vitiligo. You must have tried at least one type of topical treatment for at least three
months. No previous dyspigmentation therapy for non-segmental vitiligo.
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTRIf you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.